Linezolid Kabi (Linezolid)

Linezolid belongs to the oxazolidinone class and works by binding to the 50S subunit of bacterial ribosomes. This binding prevents the formation of the initiation complex needed for protein synthesis, thereby inhibiting bacterial growth and providing a bacteriostatic effect against susceptible Gram‑positive organisms.

The dosage of Linezolid Kabi is determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and other clinical factors. Healthcare professionals set the appropriate dosing regimen according to current guidelines and individual patient needs.

The safety of Linezolid Kabi in pregnancy and lactation has not been established. It should be used only if the potential benefits justify the potential risks to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To order Linezolid Kabi, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Linezolid Kabi offers oral and intravenous options and provides reliable coverage against MRSA, including strains resistant to other classes such as beta‑lactams and glycopeptides. Compared with vancomycin, linezolid has excellent lung penetration and does not require therapeutic drug monitoring, though it carries a distinct safety profile that must be considered.

Linezolid Kabi should be stored at room temperature, below 25 °C. Keep the vials in their original packaging, protect them from light and moisture, and avoid exposure to extreme temperatures to maintain product stability.

Linezolid Kabi is administered intravenously by slow infusion, typically over 30–60 minutes, as directed by the prescribing clinician. Administration should be performed in a clinical setting with appropriate aseptic technique and monitoring for any infusion‑related reactions.

Serious risks include thrombocytopenia, anemia, peripheral neuropathy, serotonin syndrome when combined with serotonergic drugs, and rare cases of lactic acidosis or severe allergic reactions. Patients should be monitored regularly for hematologic changes and signs of neuropathy, and clinicians should avoid concomitant use with serotonergic agents.

Linezolid Kabi should be avoided in patients with known hypersensitivity to linezolid or any component of the formulation. It is also contraindicated in individuals taking monoamine oxidase inhibitors or other serotonergic agents due to the risk of serotonin syndrome, and in patients with severe, uncontrolled myelosuppression.